Schlieren - InSphero, which specializes in 3D cell culture technologies, is offering its MASH CALL initiative to the drug discovery community. It enables the rapid identification and comparison of therapeutic candidates for the clinical treatment of non-alcoholic fatty liver inflammation (MASH).

InSphero, which describes itself as the global leader in 3D cell culture technologies for drug discovery, has announced the launch of its MASH CALL initiative. According to a statement, it is designed to enable the rapid and reliable identification and comparison of therapeutic candidates for the clinical treatment of MASH.

MASH (metabolic dysfunction-associated steatohepatitis), formerly known as NASH, is inflammation of the liver (hepatitis) that occurs as part of fatty liver disease (steatosis hepatis) and is not caused by alcohol consumption. InSphero writes that over 115 million people worldwide are affected by this complex disease.

InSphero's 3D in vitro MASH model reportedly reflects the complexity of MASH disease and enables a more comprehensive understanding of the impact and efficacy of drugs on the different facets of disease physiology. “We believe that the MASH CALL provides a unique opportunity to help the identification of MASH therapies with a cost-effective and fast candidate screening approach,” commented Dr. Francisco Verdeguer, Vice President, Liver Disease at InSphero. He describes it as “a great resource” to test not only multiple candidates but also drug combinations. 

InSphero is a spin-off from the University of Zurich and the Federal Institute of Technology in Zurich. It is headquartered in the Bio-Technopark Schlieren-Zurich in the canton of Zurich. ce/mm

Meet with an expansion expert

Our services are free of charge and include:

  • Introduction to key contacts in industry, academia, and government
  • Advice on regulatory framework, taxes, labor, market, and setting up a company
  • Custom-made fact-finding visits, including office and co-working space